INTRODUCTION: Pharmacologic blood pressure elevation is often utilized to prevent or treat ischemia in patients with acute neurologic injury, and routinely requires administration of vasopressor agents. Depending on the indication, vasopressor agents may be administered to treat hypotension or to induce hypertension. METHODS: Although numerous guideline statements exist regarding the management of blood pressure in these patients, most recommendations are based largely on Class III evidence. Further, there are few randomized controlled trials comparing vasopressor agents in these patients and selection is often guided by expert consensus. RESULTS: We discuss the clinical evidence regarding vasopressor administration for blood pressure management in patients with acute neurologic injury. The effect of various vasopressors on cerebral hemodynamics is also discussed. CONCLUSION: Although high-quality clinical data are scarce, the available evidence suggests that norepinephrine should be considered as the vasopressor of choice when blood pressure elevation is indicated in patients with acute neurologic injury.
INTRODUCTION: Pharmacologic blood pressure elevation is often utilized to prevent or treat ischemia in patients with acute neurologic injury, and routinely requires administration of vasopressor agents. Depending on the indication, vasopressor agents may be administered to treat hypotension or to induce hypertension. METHODS: Although numerous guideline statements exist regarding the management of blood pressure in these patients, most recommendations are based largely on Class III evidence. Further, there are few randomized controlled trials comparing vasopressor agents in these patients and selection is often guided by expert consensus. RESULTS: We discuss the clinical evidence regarding vasopressor administration for blood pressure management in patients with acute neurologic injury. The effect of various vasopressors on cerebral hemodynamics is also discussed. CONCLUSION: Although high-quality clinical data are scarce, the available evidence suggests that norepinephrine should be considered as the vasopressor of choice when blood pressure elevation is indicated in patients with acute neurologic injury.
Authors: Joshua B Bederson; E Sander Connolly; H Hunt Batjer; Ralph G Dacey; Jacques E Dion; Michael N Diringer; John E Duldner; Robert E Harbaugh; Aman B Patel; Robert H Rosenwasser Journal: Stroke Date: 2009-01-22 Impact factor: 7.914
Authors: M R Mayberg; H H Batjer; R Dacey; M Diringer; E C Haley; R C Heros; L L Sternau; J Torner; H P Adams; W Feinberg Journal: Stroke Date: 1994-11 Impact factor: 7.914
Authors: Stefan-Nikolaus Kroppenstedt; Ulrich-Wilhelm Thomale; Martin Griebenow; Oliver W Sakowitz; Klaus-Dieter Schaser; Petra S Mayr; Andreas W Unterberg; John F Stover Journal: Crit Care Med Date: 2003-08 Impact factor: 7.598
Authors: A E Hillis; J A Ulatowski; P B Barker; M Torbey; W Ziai; N J Beauchamp; S Oh; R J Wityk Journal: Cerebrovasc Dis Date: 2003 Impact factor: 2.762
Authors: Luzius A Steiner; Jonathan P Coles; Andrew J Johnston; Marek Czosnyka; Tim D Fryer; Peter Smielewski; Doris A Chatfield; Raymond Salvador; Franklin I Aigbirhio; John C Clark; David K Menon; John D Pickard Journal: J Cereb Blood Flow Metab Date: 2003-11 Impact factor: 6.200
Authors: F Altaf; D E Griesdale; L Belanger; L Ritchie; J Markez; T Ailon; M C Boyd; S Paquette; C G Fisher; J Street; M F Dvorak; B K Kwon Journal: Spinal Cord Date: 2016-06-07 Impact factor: 2.772
Authors: Raoul Sutter; Gian Marco De Marchis; Saskia Semmlack; Peter Fuhr; Stephan Rüegg; Stephan Marsch; Wendy C Ziai; Peter W Kaplan Journal: CNS Drugs Date: 2017-01 Impact factor: 5.749
Authors: Marc Soubeyrand; Arnaud Dubory; Elisabeth Laemmel; Charles Court; Eric Vicaut; Jacques Duranteau Journal: Eur Spine J Date: 2013-11-14 Impact factor: 3.134